Phase II study of combination chemotherapy with TS-1/irinotecan and bevacizumab as second-line therapy in patient with K-RAS mutation-type metastatic colorectal cancer
- Conditions
- advanced/metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000005900
- Lead Sponsor
- PO FMPC (Future Medicine Promoting Consortium)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
(1) History of serious drug hypersensitivity (2) Women who are pregnant,lactating,or wish to become pregnant or men who expect babies. (3) Severe infectious disease (4) Serious complications (5) Clinically significant heart disease (6) Gastrointestinal ulceration or bleeding (7) Watery diarrhea (8) Uncontrolable pleural effusion or ascites requiring (9) Symptomatic brain metastases (10) Current or previous (within the last 6months) history of GI perforation (11) Previous history of thrombosis,cerebral infarction,pulmonary infarction,hemoptysis and interstitial pneumonia (12) were operated within 28days before entry (13) Evidence of bleeding diathesis or coagulopathy (14) ongoing treatment with anticoagulant (15) had active double cancer (16) Systemic administration of corticosteroids (17) Patients judged inappropriate for this study by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method